ABSTRACT
BACKGROUND Cognitive function was significantly associated with post-stroke depression and anxiety in stroke patients. However, no studies have examined whether there is an interaction. this study purposed to investigate whether cognitive function mediates the effect of enrollment in post-acute care (PAC) programs on depression or anxiety in stroke patients and whether the indicators are moderated in the pathway.
METHODS This is a prospective observational cohort study. A group of patients who had received PAC for stroke at one of two medical centers (PAC group, n = 2,087) was compared with a group who had received standard care for stroke at one of four hospitals (three regional hospitals and one district hospital; non-PAC group, n = 1,591) in Taiwan from March, 2015, to March, 2022. The effects of PAC on cognitive function and depression and anxiety at baseline, 12th week, and 1st year after rehabilitation were investigated using structural equation modeling (SEM). The effect of each variable on the moderation of different pathways in the model was analyzed using AMOS 23.0, and The SPSS PROCESS macro also was used to perform mediation analysis.
RESULTS The PAC program had a mediating effect on cognition and depression at week 12 (a*b= -0.098, P<0.05) on cognition and anxiety at week 12 (a*b= -0.107, P<0.05), and the PAC program had a direct effect on depression and anxiety in the first year. It was found that acute lengths of stay had a significant moderation effect in the model (X*W→M=0.204, P=0.002), but the model lost its mediating effect when the moderation variable was added.
CONCLUSIONS Patients with stroke should receive post-acute care as soon as possible to improve their cognitive function after rehabilitation, to maximize the effectiveness of treatment for mental disorders, and to reduce the burden of the disease.
WHAT IS KNOWN
Research suggests that cognitive function, including depression and anxiety, significantly improved for patients using post-acute care (PAC).
Cognitive function was significantly associated with post-stroke depression and anxiety in patients with stroke.
WHAT THE STUDY ADDS
PAC had a mediating effect on cognition and depression at week 12 on cognition and anxiety at week 12, and it also had a direct effect on depression and anxiety in the first year.
Acute lengths of stay had a significant moderation effect in the model, but the model lost its mediating effect when the moderation variable was added.
Patients with stroke should receive post-acute care as soon as possible to improve their cognitive function after rehabilitation, to maximize the effectiveness of treatment for mental disorders, and to reduce the burden of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is NOT considered to meet the NIH definition of a clinical trial.
Funding Statement
This study was supported by funding from the Kaohsiung Medical University (KMU-DK(A)112009) and the Ministry of Science and Technology (MOST 108-2410-H-037-006-SS3 & 111-2410-H-037-002-MY3) in Tai-wan.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board of the Kaohsiung Medical University Hospital (KMUH-IRB-20140308).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets used/or analyzed during the current study are available from the corresponding author on reasonable request.
